Monitoring and Management of Patients on Therapy for Chronic Hepatitis B

You answered:

A For HBeAg-positive patients, monitoring for HBeAg seroconversion should occur only after the patient has achieved HBsAg seroconversion.

This answer is incorrect. For patients who are HBeAg-positive at baseline, monitoring for loss of HBeAg is strongly recommended and is considered an important parameter to follow. If HBeAg seroconversion does occurs, it will take place before HBsAg seroconversion. Thus, waiting for HBsAg seroconversion to occur before monitoring for HBeAg seroconversion would not be logical. Further, the likelihood of HBsAg seroconversion is extremely low and markedly less probable than HBeAg seroconversion.

Choose another answer:

B After starting therapy, the patient should have his ALT and HBV DNA level next measured at the end of 1 year of therapy.
C As soon as the patient obtains an undetectable HBV DNA level, it is advisable for him to stop therapy.
D If the patient’s HBV DNA level declines by 1 log10 after 6 months of therapy, the response is termed a primary non-response.

[Back to Question | Go to Correct Answer]